This article has Open Peer Review reports available.
Partitioning of excess mortality in populationbased cancer patient survival studies using flexible parametric survival models
 Sandra Eloranta^{1}Email author,
 Paul C Lambert^{1, 2},
 Therese ML Andersson^{1},
 Kamila Czene^{1},
 Per Hall^{1},
 Magnus Björkholm^{3} and
 Paul W Dickman^{1}
https://doi.org/10.1186/147122881286
© Eloranta et al.; licensee BioMed Central Ltd. 2012
Received: 18 August 2011
Accepted: 24 June 2012
Published: 24 June 2012
Abstract
Background
Relative survival is commonly used for studying survival of cancer patients as it captures both the direct and indirect contribution of a cancer diagnosis on mortality by comparing the observed survival of the patients to the expected survival in a comparable cancerfree population. However, existing methods do not allow estimation of the impact of isolated conditions (e.g., excess cardiovascular mortality) on the total excess mortality. For this purpose we extend flexible parametric survival models for relative survival, which use restricted cubic splines for the baseline cumulative excess hazard and for any timedependent effects.
Methods
In the extended model we partition the excess mortality associated with a diagnosis of cancer through estimating a separate baseline excess hazard function for the outcomes under investigation. This is done by incorporating mutually exclusive background mortality rates, stratified by the underlying causes of death reported in the Swedish population, and by introducing cause of death as a timedependent effect in the extended model. This approach thereby enables modeling of temporal trends in e.g., excess cardiovascular mortality and remaining cancer excess mortality simultaneously. Furthermore, we illustrate how the results from the proposed model can be used to derive crude probabilities of death due to the component parts, i.e., probabilities estimated in the presence of competing causes of death.
Results
The method is illustrated with examples where the total excess mortality experienced by patients diagnosed with breast cancer is partitioned into excess cardiovascular mortality and remaining cancer excess mortality.
Conclusions
The proposed method can be used to simultaneously study disease patterns and temporal trends for various causes of cancerconsequent deaths. Such information should be of interest for patients and clinicians as one way of improving prognosis after cancer is through adapting treatment strategies and followup of patients towards reducing the excess mortality caused by side effects of the treatment.
Keywords
Survival analysis Cancer Relative survival Regression models Competing risksBackground
Observational studies of cancer patient survival often use data recorded by populationbased cancer registries and are typically analyzed using relative survival. Relative survival is defined as the observed (allcause) survival, S(t), among the cancer patients divided by the expected survival, ^{ S∗}(t), in a comparable group (with respect to age, sex, calendar year and possibly other covariates) in the general population. On the hazard scale, relative survival provides a measure of excess mortality that can be assumed to be entirely, directly or indirectly, attributable to the disease [1]. One reason for why modelling excess mortality has become the preferred method for populationbased cancer patient survival analysis is that it not only captures deaths that are directly due to the cancer in question but also deaths that can be thought of as indirect or cancerconsequent, without relying on the classification of cause of death. There are, however, research areas of clinical interest that involve estimating the effect of one particular component of the excess mortality and existing methodology does not provide an immediate answer to how such an analysis might be carried out. For example, late adverse health effects in cancer patients is a growing problem given the longer survival seen for most cancers. Causespecific survival in breast cancer patients is far better today than 20 years ago probably due to intensified mammography screening and more prevalent use of adjuvant therapy such as antihormones and chemotherapy. Several studies have, however, identified an increasing risk of cardiovascular disorders, mainly myocardial infarction, possibly associated with radio and chemotherapy such as anthracyclines, in breast cancer survivors. If the primary interest lies in studying temporal trends in treatmentrelated mortality following a diagnosis of breast cancer, how can we best identify the deaths that occur as a consequence of the treatment? It is wellknown that radiotherapy and chemotherapy following a breast cancer diagnosis cause cardiac dysfunction and increase cardiovascular mortality more than 15 years after diagnosis and hence indirectly contribute to excess breast cancer mortality [2–4]. These deaths are particularly difficult, if at all possible, to identify solely based on the information stated on the death certificate. The reason is that a correct classification of death due to treatmentinduced cardiovascular disease (CVD) would require knowledge about which cardiovascular deaths would not have occurred in the absence of a cancer diagnosis. Previous work in this area has involved comparing CVD specific mortality ratios by laterality in women treated with radiotherapy compared to women who did not receive radiotherapy treatment [5] or via modelling of standardized mortality ratios [6]. The first approach is often not appropriate for cancer register data where treatment is, if recorded, not randomized. Moreover, both approaches analyse the excess CVD mortality as an isolated condition, ignoring the fact that the excess CVD mortality is only one component of the excess mortality, and thus the possibility that certain covariate effects can be assumed to be equal for the different component parts. In situations where one of the events is rare such assumptions may become necessary to avoid overfitting the model [7]. Pintilie and others [8] have recently suggested a casecohort approach to estimating treatmentrelated mortality in patients diagnosed with Hodgkin lymphoma while simultaneously accounting for competing causes of death by borrowing ideas from Fine and Gray [9]. We suggest an alternative approach, building on work of Royston and Parmar [10] on flexible parametric survival models and later adapted for relative survival by Nelson et al. [11]. The latter models are fitted on the log cumulative excess hazard scale using restricted cubic splines [12] for the baseline excess hazard and for any timedependent effects. By borrowing ideas from classical competing risks theory and incorporating background mortality rates, stratified by the reported underlying causes of death, reported in the Swedish population we propose a model that simultaneously models the number of CVDdeaths and remaining deaths (i.e., deaths other than CVD deaths) among the cancer patients that occur in excess to what is expected in a cancerfree population.
Crude probabilities of death due to cancer and other causes can be derived using the theory of competing risks and have previously been shown to be particularly useful under circumstances where it is of interest to communicate cancer prognosis while accounting for the fact that cancer patients are at risk of experiencing mortality due to a wide range of other causes than their cancer. Cronin et al. showed how the crude probability of death due to cancer and other causes can be calculated from lifetables [13]. The theory has subsequently been further developed by Lambert et al. to show how the crude probabilities of death can be calculated after fitting a flexible parametric relative survival model to individual patient data [14]. In this paper we show how the excess hazard functions, related to the different outcomes under investigation, can be used further to partition the crude probabilities of death into component parts (i.e., death due to excess CVD or other cancerrelated causes).
The proposed methodology is illustrated using women diagnosed with breast cancer in Sweden between 19731992 and followed up for a maximum of 15 years. The paper is outlined as follows: The Methods section describes relative survival, flexible parametric models for relative survival and provides a framework for how flexible parametric models are adopted for modelling competing risks. The Results and discussion section describes the breast cancer application, implements the method on this data set, and discusses the assumptions of the models. Potential areas for future development and refinement are discussed in the Conclusions section of the paper.
Methods
Excess mortality and relative survival
where ^{ S∗}(t) is the expected survival and R(t) is the relative survival at time t. Both ^{ S∗}(t) and ^{ h∗}(t) are assumed known and are usually obtained from routine data sources (e.g., national or regional life tables).
Flexible parametric models
Here the log cumulative baseline excess hazard is represented by restricted cubic splines for ln(t), $s\left(\text{ln}\right(t);{\gamma}_{\mathbf{0}},{\mathbf{k}}_{0})$, characterised by the vector of knot positions, k _{0}, and the vector of parameters associated with the spline variables, γ _{ 0 } and where the effects of covariates, x, are given by β. The derivation of the spline function has been described in detail elsewhere [10].
Timedependent effects
where D is the number of timedependent covariate effects and $s\left(\text{ln}\right(t);{\gamma}_{\mathbf{i}},{\mathbf{k}}_{i})$ is the spline function for the i ^{ th } timedependent effect. Note that for each of the D timedependent effects represented by x _{ i } in the model above are typically a subset of x.
Flexible parametric survival models have advantages over Poisson regression models for excess mortality, which fit piecewise constant effects for the baseline excess hazard rate, as they obviate the need for splitting the time scale into a number of intervals. In contrast to equation 5, a piecewise approach, with a reasonable number of split points, typically implies estimating a large number of parameters for the timedependent effects. A number of alternative approaches to model λ(t) have however also been proposed [15–18]. While the most common solution for handling timedependent covariate effects is via inclusion of interaction terms between the covariates that depend on time and the timescale, alternative approaches for assessing timedependence and goodnessoffit have also been proposed [18, 19].
In the current application of flexible parametric models the outcome is mortality. For this reason we will use the term excess mortality, in place of excess hazard. The latter is, in most applications of survival analysis, regarded as the generic term for any timetoevent outcome and the reader may think of the terms as being exchangeable.
Flexible parametric models for componentspecific excess mortality
where other is used to denote deaths due to other causes than CVD. Written on this form, ${H}_{\text{cvd}}^{\ast}\left(t\right)$ and ${H}_{\text{other}}^{\ast}\left(t\right)$ represent the expected mortality from CVD and other causes respectively and are assumed known from national mortality statistics. Θ(t)_{ cvd } is our main quantity of interest and represents the excess CVD mortality rate among the patients whereas Θ(t)_{ other }represents the remaining excess mortality rate attributable to the cancer. The main contribution to Θ(t)_{ other } comes from deaths from the underlying disease (breast cancer in this case), but side effects other than CVD, such as second malignancies contribute to the remaining excess hazard too.
and where $s\left(\text{ln}\right(t);{\gamma}_{0},{\mathbf{k}}_{0})$ now represents the log cumulative baseline excess mortality function for causes other than excess CVD, β _{ cvd } the parameter that represents the shift in the baseline excess function if interest is in the excess CVD mortality, and $s(ln(t);{\gamma}_{\text{cvd}},{\mathbf{k}}_{\text{cvd}})$ the timedependent effect that allows the baseline excess mortality function for the excess CVD mortality to vary freely. In this example, ^{ x T } βdenotes the effect of the covariates that are assumed common for the two causes whereas ${\mathbf{x}}^{T}{\mathit{\beta}}_{\text{cvd}}$ represents interaction effects (i.e., the additional covariate effects for modelling the excess CVD mortality). Furthermore, additional complexity such as timedependent covariate effects can easily be accommodated by including additional interaction terms with a spline term representing the underlying time scale (see equation 5 for details).
The individual contribution to the log likelihood for a flexible parametric model on the log cumulative hazard scale is described in detail in [20]. Stata’s stpm2 module [20] was used to applying the proposed model to women with breast cancer in Sweden. The stpm2 module is a readily available userwritten program which uses Stata’s optimizer, ml (which in turn uses the NewtonRaphson algorithm) to maximize the likelihood function.
Estimating crude treatmentrelated mortality
The integrands in equations 910 and 11 are nonlinear functions of the model parameters and the integrals are obtained numerically by splitting the time scale into a large number, n, of small intervals and summing the values of the integrand for the n time intervals. 95% confidence intervals are retrieved using the delta method. For a detailed description of the method used for the numerical integration and for calculation of confidence intervals see Lambert et al[14].
Application to breast cancer in Sweden  Description of the data
We obtained a data set encompassing all female breast cancer registrations in Sweden between 1 January 1973 and 31 December 1992 from the National Swedish Cancer Register [21]. All women had a potential followup of at least 15 years. Among the 70,655 women there were 8,939 deaths where the underlying cause of death was classified as CVD and 31,422 deaths where the underlying cause of death was classified as other than CVD. Causespecific background mortality rates were created by combining publically available national mortality statistics with populationbased information about the underlying cause of death reported to the Swedish Cause of Death Register 19732007. A detailed description of this procedure is provided in the appendix.
Results and discussion
Proportional excess hazards model
Time since diagnosis, estimated using survival times in days, was used as the underlying time scale. We fitted a proportional excess hazard model where age at diagnosis and calendar year of diagnosis were included as categorical variables. Interaction terms between age at diagnosis and cause of death and between calendar period and cause of death were included to allow the effect to differ for the two outcomes respectively. The log cumulative baseline excess mortality functions for both outcomes were modeled using restricted cubic splines with 5 df. The knots were places at the 0th, 20th, 40th, 60th, 80th and 100th centiles of the uncensored log event times. For comparison we also fitted a proportional excess mortality model for the total excess mortality (i.e., without partitioning the excess mortality into component parts). All reported pvalues refer to results from likelihood ratio tests.
The estimated excess mortality rate ratios (EMRR) from the two models are shown in table 1. The EMRRs for the total excess mortality and the remaining (nonCVD) excess mortality are very similar. This is expected because the excess CVD deaths only constitute a relatively small portion of the total excess mortality. The effect of age at diagnosis on excess CVD mortality is more pronounced than for the excess remaining mortality (p for interaction < 0.001). The predicted excess CVD mortality rate for women aged 7079 was 5.32 (95 % CI: 3.518.06) times higher than that of women aged 5059 at diagnosis whereas the corresponding EMRR for the remaining excess mortality was 1.09 (1.041.14). There was no evidence against the hypothesis of a common effect of calendar period on the excess mortality for the two outcomes (p = 0.292).
Parameter estimates from flexible parametric models
Covariate  EMRR (CVD)  EMRR (remaining)  EMRR (total) 

< 50  0.40 (0.240.69)  0.96 (0.921.00)  0.95 (0.910.99) 
5059  1.00 (reference)  1.00 (reference)  1.00 (reference) 
6069  1.84 (1.162.91)  0.99 (0.951.03)  1.00 (0.961.04) 
7079  5.32 (3.518.06)  1.09 (1.041.14)  1.11 (1.061.16) 
19731977  1.00 (reference)  1.00 (reference)  1.00 (reference) 
19781982  1.13 (0.681.87)  0.82 (0.790.85)  0.82 (0.790.86) 
19831987  1.23 (0.762.01)  0.76 (0.730.79)  0.78 (0.750.81) 
19881993  0.76 (0.451.31)  0.58 (0.560.60)  0.59 (0.560.61) 
Nonproportional excess hazards models
Crude probability of cancer death
The three bottom graphs of Figure 5 show the relative contribution of each component part, as well as death due to other causes, to the total mortality. Hence, by conditioning on that a woman, diagnosed in 1992 and aged 55, 65 or 75 years respectively at diagnosis, has died by time t, these graphs illustrate the proportion of all deaths estimated to be due to each possible cause of death. For all three age categories, the proportion of cancer deaths (excluding excess CVD deaths) decrease with elapsed time since diagnosis whereas the opposite is observed for deaths due to other causes than cancer. In contrast, the excess CVD deaths remain quite constant throughout the 15 years of followup.
Assumptions and sensitivity analyses
There are two key assumptions for the proposed approach for partitioning the excess mortality into component parts. Firstly, although cause of death information is not used directly to identify patients who were reported to die from excess CVD (due to the inherent difficulty of determining whether the death would have occurred had the women not have been treated from breast cancer) it is used indirectly to determine the number of CVD deaths that occur in excess to what is expected in a population free of breast cancer. In order to study the impact of potential misclassification of CVDevents in the cause of death recordings obtained from Swedish official statistics we calculated the proportion of the observed CVD deaths that would have had to be coded erroneously in order to reduce the excess CVD mortality by 10, 15 and 20 percent respectively. The results, including also the observed and expected CVD counts in the data (stratified by age at diagnosis and year of diagnosis), are presented in table 2. The results show that, irrespective of covariate pattern, a misclassification of 6 to 7 % of the CVD deaths would decrease the excess CVD deaths by 10%. Nyström et al. [23] have previously examined the quality of the cause of death classification of 282,777 women (1,296 deaths) who participated in the Swedish randomized mammography trials between the years 1976 and 1982. The authors retrieved copies of medical records including autopsy protocols, death certificates, and histopathology reports and set up an end point committee to review the information relevant for assessment of the cause of death and found a high concordance concerning breast cancer as underlying cause of death with the information reported to the official statistics bureau in Sweden. The study supports the use of official health statistic in the evaluation of the Swedish screening trials. In this study cause of death was stratified on cardiovascular outcomes but the findings of Nyström et al. are nevertheless relevant even in this setting as they suggest that we are not likely to underestimate CVD deaths in this study as a consequence of breast cancer deaths being reported more frequently among the patients than they would in a disease free population. However, we recommend careful considerations of the quality of the national statistics prior to applying this method in other settings.
Sensitivity of causeofdeath classification
At risk  Observed CVD deaths  Expected CVD deaths  Excess deaths (ED)  Proportion of misclassified CVD deaths required to reduce the ED:s by 10,15 and 20 %  

10%  15%  20%  
Year of Diagnosis:  
19731977  
≤49 years  3339  35  11.9  23.1  6.6  10.0  13.1 
5059 years  3713  127  42.4  84.6  6.7  10.0  13.3 
6069 years  4522  600  205.3  394.7  6.6  9.9  13.2 
7079 years  4009  1313  621.8  691.2  5.3  7.9  10.5 
Year of Diagnosis:  
19781982  
≤49 years  3447  28  10.5  17.5  6.4  9.3  12.5 
5059 years  3750  127  42.1  84.9  6.7  10.0  13.4 
6069 years  4933  607  219.4  387.6  6.4  9.6  12.8 
7079 years  4898  1592  733.7  859.3  5.4  8.1  10.8 
Year of Diagnosis:  
19831987  
≤49 years  3894  29  9.5  19.5  6.9  10.0  13.4 
5059 years  3463  122  33.5  88.5  7.3  10.9  14.5 
6069 years  5055  571  203.1  367.9  6.4  9.7  12.9 
7079 years  5155  1554  696.3  857.7  5.5  8.3  11.0 
Year of Diagnosis:  
19881992  
≤49 years  4640  44  12.2  31.8  7.3  10.9  14.5 
5059 years  4308  106  40.5  65.5  6.2  9.2  12.4 
6069 years  6200  598  240.6  357.4  6.0  9.0  12.0 
7079 years  5329  1485  630.9  854.1  5.8  8.6  11.5 
Secondly, relative survival analyses require the assumption that survival from the disease under study is independent of survival from other causes. The patients are also assumed to be exchangeable to the background population had they not been diagnosed with cancer. In the current study where we in fact study two outcomes in parallel the independence assumption is applied twice. Firstly, in order to accurately estimate excess CVD mortality among the patients we assume that the CVD risk among the patients (in the absence if cancer) is the same as the risk in the general population conditional on age, calendar year and sex. An equivalent assumption is also made for the remaining excess mortality. It is known, due to a differential distribution of risk factors, that the risk for breast cancer is greater among women from higher social classes, indicating that the distribution social class differs between patients and the general population. This suggests that the assumption of exchangeability may be violated as the background mortality rates are not stratified on social class. If this is the case the comparison population used is likely to have worse survival than what we would expect under independence. This could potentially bias the excess mortality rates for the component parts downwards suggesting that the observed estimates may, to some degree be, underestimated. It has, however, been demonstrated previously that such a bias is negligible in situations when the primary objective of the study is not to compare patient survival by social class [24].
Lastly, flexible parametric models use restricted cubic splines for modelling the log cumulative baseline excess mortality rate. Lambert et al. [14, 20] have previously shown that the excess mortality rates are robust to the choice of number and placement of the knots used to define the spline terms. As a sensitivity analysis we fitted 6 models, all similar to the model described in the first part of section Crude probability of cancer death, to study the impact of the configuration of the knots used for modelling the componentspecific baseline excess mortality rates as well as the restricted cubic splines involved in estimating the timedependent effects of age and calendar year on the predicted excess mortality rates. Table 3 shows the distribution of knots used for each model (including model a) which generated figure 2) as well as the associated AIC (Akaike information criterion) and BIC (Bayesian information criterion). Varying degrees of freedom were used for the baseline log cumulative excess hazards, d f _{ b } and the timedependent effects of the covariates, d f _{ t }(covariate × time interaction). Figure 7 shows that the estimated excess mortality for the different models are very insensitive to the placement and number of knots used to model the spline terms. We do recognize from table 3 that the model a) is formally not the bestfitting model, based on the reported AIC or the BIC, but given the descriptive purposes of this application and the fact that the models provide extremely similar estimates of the excess mortality rates it was nevertheless used for demonstration of the method.
Sensitivity to knot configuration
Model  Baseline, d f _{ b }  Age, d f _{ a }  Year, d f _{ y }  Number of parameters  AIC  BIC 

a  5  3  3  38  304202  304537 
b  4  3  3  36  304219  304537 
c  3  3  3  34  304291  304592 
d  5  2  3  35  304207  304517 
e  5  4  3  41  304165  304527 
f  5  3  2  35  304197  304507 
g  5  3  4  41  304204  304565 
Conclusions
We have shown how excess mortality due to cancer can be partitioned into component parts by fitting a flexible parametric survival model stratified on cause of death. The model is useful for simultaneously studying disease patterns and temporal trends for defined causes of cancerconsequent deaths. We have illustrated this by studying trends in the excess CVD mortality and remaining excess mortality among patients who have been exposed to a potentially cardiotoxic treatment following a diagnosis of breast cancer. These excess mortality rates quantify the transition rates to the events of interest in the situation where the patients are allowed to experience either of the events under investigation. The main advantage of modelling the different endpoints simultaneously is that, in contrast to fitting separate models for each outcome, it allows us to assume that the effects of some covariates are common for all outcomes. Moreover, likelihoodratio tests or Wald tests may be used to formally assess this assumption [7].
In addition, we have shown how the model estimates may be used postestimation to calculate crude probabilities of death due to the component parts. The two methods help to answer different questions but the crude probabilities of death will generally be of more interest to clinicians and patients when making decisions about treatments as these estimates provide an estimate of the probability of dying from, for example, treatmentrelated CVD in the presence of other causes of death.
Future directions
The proposed model offers a possibility to monitor temporal trends in treatmentrelated excess mortality. From a public health perspective, being able to study if changes in clinical practise towards reducing treatmentrelated mortality have had an impact on patient survival is clearly of importance. In this article we chose to apply the method to study excess CVD among women with breast cancer, but we believe the basic idea of the method is useful also in other applications. Possible extensions of the method described in this paper include additional partitioning of the excess mortality. For example, an increased risk of lung cancer following treatment with radiotherapy has been reported among women with breast cancer [25]. Similarly, treatment for Hodgkin lymphoma has also been reported to increase the risk for secondary malignancies [26]. Finer partitioning of excess cancer mortality would, however, require additional use of the information stated on the death certificates and further work should address under what situations finer stratification is feasible. Moreover, because lifetables stratified on cause of death are typically not readily available, additional work examining the possible need for applying different smoothing techniques on the expected mortality rates might be of particular importance for studying rare outcomes.
Another interesting possible extension of the model would be to combine the proposed model with statistical cure models. Cure models within the framework of flexible parametric models have recently been proposed as an alternative to parametric cure models [27]. A limitation of cure models is that they are not appropriate unless longterm excess mortality tends to zero (i.e., a cure proportion exists). If the longterm excess mortality is due to one specific cause (e.g., excess CVD) then we can potentially partition out that component and subsequently fit a cure model. For example, combining the two proposed methodologies would allow for estimation of the a theoretical cure proportion after having partitioned out the excess mortality due to excess CVD mortality among patients diagnosed with lung cancer.
Appendix
Methods for generating lifetables stratified on cause of death
Data

ICD7(19611968):400468,

ICD8(19691986):390458,

ICD9(19871996):390459 and

ICD10(19972007):I00I99.
The lifetables used in the analysis were stratified based on the underlying cause of death only, leaving 2,051,269 (77%) recorded cardiovascular events in the raw data. Of these, individuals older than 99 at the time of death were excluded (n = 520).
Data on the total number of deaths in Sweden as well as population counts, stratified on age, sex and calendar time was obtained in period format i.e., by year of occurence) from the Human Mortality Database (HMD) [28]. The HMD is a collaborative project sponsored by the University of Berkeley and the Max Planck Institute for Demographic Research. The raw data consist of birth and death counts from vital statistics plus population counts from official population estimates. A detailed documentation of the data cleaning [29] of raw data files is published on the HMD webpage [28].
Calculation of causespecific death rates
The causespecific event rates were subsequently merged to the cancer patient data set (reshaped into long format) with respect to sex, age and year at each patient’s event time.
Declarations
Acknowledgements
This work was financially supported by the Swedish Cancer Society (Cancerfonden, grant number: CAN 2010/676). The authors would also like to thank the reviewers for their valuable comments related to this manuscript.
Authors’ Affiliations
References
 Perme MP, Stare J, Estève J: On Estimation in Relative Survival. Biometrics. 2012, 68 (1): 11310.1111/j.15410420.2011.01640.x.View ArticlePubMedGoogle Scholar
 Bird BR, Swain SM: Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008, 14: 1410.1158/10780432.CCR071033.View ArticlePubMedGoogle Scholar
 Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Møller H: Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a populationbased study. BMC Cancer. 2007, 7: 910.1186/1471240779.View ArticlePubMedPubMed CentralGoogle Scholar
 Violet JA, Harmer C: Breast cancer: improving outcome following adjuvant radiotherapy. Br J Radiol. 2004, 77 (922): 81110.1259/bjr/44576710.View ArticlePubMedGoogle Scholar
 Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A: Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. BMJ. 2003, 326 (7383): 25610.1136/bmj.326.7383.256.View ArticlePubMedPubMed CentralGoogle Scholar
 Hooning M, Aleman BM, van Rosmalen AJ, Kuenen MA, Klijn JG, van Leeuwen FE: Causespecific mortality in longterm survivors of breast cancer: A 25year followup study. Int J Radiat Oncol Biol Phys. 2006, 64 (4): 108110.1016/j.ijrobp.2005.10.022.View ArticlePubMedGoogle Scholar
 Putter H, Fiocco M, Geskus R: Tutorial in biostatistics: competing risks and multistate models. Stat Med. 2007, 26 (11): 238910.1002/sim.2712.View ArticlePubMedGoogle Scholar
 Pintilie M, Bai Y, Yun L, Hodgson DC: The analysis of case cohort design in the presence of competing risks with application to estimate the risk of delayed cardiac toxicity among Hodgkin Lymphoma survivors. Stat Med. 2010, 29 (27): 280210.1002/sim.4056.View ArticlePubMedGoogle Scholar
 Fine J, Gray R: A proportional hazards model for the subdistribution of a competing risk. JASA. 1999, 94: 496View ArticleGoogle Scholar
 Royston P, Parmar MK: Flexible parametric proportionalhazards and proportionalodds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002, 21 (15): 217510.1002/sim.1203.View ArticlePubMedGoogle Scholar
 Nelson CP, Lambert PC, Squire IB, Jones DR: Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med. 2007, 26 (30): 548610.1002/sim.3064.View ArticlePubMedGoogle Scholar
 Durrleman S, Simon R: Flexible regression models with cubic splines. Stat Med. 1989, 8 (5): 55110.1002/sim.4780080504.View ArticlePubMedGoogle Scholar
 Cronin KA, Feuer EJ: Cumulative causespecific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med. 2000, 19 (13): 172910.1002/10970258(20000715)19:13<1729::AIDSIM484>3.0.CO;29.View ArticlePubMedGoogle Scholar
 Lambert P, Dickman P, Nelson C, Royston P: Estimating the crude probability of death due to cancer and other causes using relative survival models. Stat Med. 2010, 29 (78): 88510.1002/sim.3762.View ArticlePubMedGoogle Scholar
 Dickman PW, Sloggett A, Hills M, Hakulinen T: Regression models for relative survival. Stat Med. 2004, 23: 5110.1002/sim.1597.View ArticlePubMedGoogle Scholar
 Perme MP, Henderson R, Stare J: An approach to estimation in relative survival regression. Biostatistics. 2009, 100: 136Google Scholar
 McKeague I, Sasieni P: A partly parametric additive risk model. Biometrica. 1994, 81: 50110.1093/biomet/81.3.501.View ArticleGoogle Scholar
 Cortese G, Scheike TH: Dynamic regression hazards models for relative survival. Stat Med. 2008, 27 (18): 356310.1002/sim.3242.View ArticlePubMedPubMed CentralGoogle Scholar
 Stare J, Pohar M, Henderson R: Goodness of fit of relative survival models. Stat Med. 2005, 24 (24): 391110.1002/sim.2414.View ArticlePubMedGoogle Scholar
 Lambert P, Royston P: Further development of flexible parametric models for survival analysis. The Stata J. 2010, 9 (2): 265Google Scholar
 Barlow L, Westergren K, Holmberg L, Talbäck M: The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009, 48: 2710.1080/02841860802247664.View ArticlePubMedGoogle Scholar
 Taylor CW, Brønnum D, Darby SC, Gagliardi G, Hall P, Jensen MB, McGale P, Nisbet A, Ewertz M: Cardiac dose estimates from Danish and Swedish breast cancer radiotherapy during 19772001. Radiother Oncol. 2011, 100 (2): 1976View ArticleGoogle Scholar
 Nystrøm L, Larsson LG, Rutqvist LE, Lindgren A, Lindqvist M, Rydén S, Andersson I, Bjurstam N, Fagerberg G, Frisell J: Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee. Acta Oncol. 1995, 34 (2): 14510.3109/02841869509093948.View ArticlePubMedGoogle Scholar
 Dickman PW, Auvinen A, Voutilainen ET, Hakulinen T: Measuring social class differences in cancer patient survival: is it necessary to control for social class differences in general population mortality? A Finnish populationbased study. J Epidemiol Community Health. 1998, 52 (11): 72710.1136/jech.52.11.727.View ArticlePubMedPubMed CentralGoogle Scholar
 Prochazka M, Hall P, Gagliardi G, Granath F, Nilsson BN, Shields PG, Tennis M, Czene K: Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: caseonly design. J Clin Oncol. 2005, 23 (30): 746710.1200/JCO.2005.01.7335.View ArticlePubMedGoogle Scholar
 Ng AK, Mauch PM: Late effects of Hodgkin’s disease and its treatment. Cancer J. 2009, 15 (2): 16410.1097/PPO.0b013e31819e30d7.View ArticlePubMedGoogle Scholar
 Andersson TM, Dickman PW, Eloranta S, Lambert PC: Estimating and modelling cure in populationbased cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol. 2011, 11: 9610.1186/147122881196.View ArticlePubMedPubMed CentralGoogle Scholar
 Human Mortality Database (data downloaded on 20100413). University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). [http://www.mortality.org]
 Wilmoth J, Andreev K, Jdanov D, Glei D: Methods protocol for the Human Mortality Database. Tech. rep., University of California, Berkeley and Max Plack Institute for Demographic Research. 2007Google Scholar
 The prepublication history for this paper can be accessed here:http://www.biomedcentral.com/14712288/12/86/prepub
Prepublication history
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.